Poziotinib PR issued today. While not the SABCS metastatic BC study PR we were hoping for it’s interesting none the less in several ways in that it shows promise in a hard to treat lung cancer population and they (MD Anderson, I assume in collaboration w SPPI) will be starting a P2 study later this year. But before they do, the abstract says they’ll need to run some in vivo studies to gather some data (I’m a little stumped by that because I would assume that they already have a bunch of that type of data from Hanmi). Here’s some info from the abstract
Edit - If they do run a P2 study I so hope that they run a pivotal one not like this current US study they are running now. Use PFS for accelerated approval and continue the study in gathering OS data for possible full approval. They have a Director on their board, Anthony Maida, whose company he works for, NWBO, is currently running one. They should use his expertise.